Kaneka offers technology solutions for monoclonal antibody (MAb) generation. In 2007, Kaneka initiated a MAb discovery program under a strategic alliance with Evec Inc., a Japanese bio-venture that has developed unique technologies to generate “fully human MAb” isolated from human peripheral B-lymphocytes. The Kaneka/Evec alliance provides pharmaceutical companies with “fully human MAb” from Evec's pipeline and a unique R&D collaboration to discover customer's desirable “fully human MAb.”
Please contact Kaneka for more business details.
|
|
|
![]()
|
KANEKA CORPORATION
QOL Division
3-2-4, Nakanoshima Kita-ku
Osaka 530-8288, Japan Tel: +81-6-6226-5377 Fax: +81-6-6226-5128 e-mail:pd@fc.kaneka.co.jp
KANEKA AMERICA LLC
QOL-Fine Chemicals
546 Fifth Avenue, 21st Floor
New York, NY 10036, USA Tel: +1-212-705-4390 Fax: +1-212-705-4350 e-mail: finechemicalsinfo@kaneka.com
KANEKA PHARMA EUROPE N.V.
Fine Chemicals Division
Triomflaan 173
1160 Brussels, Belgium Tel: +32-2-663-0340 Fax: +32-2-663-0361 e-mail: finechem@kaneka.be |

